<p><img src="https://imageproxy.pbkrs.com/https://images.unsplash.com/photo-1504639725590-34d0984388bd/query-Zm09anBnJml4aWQ9TTN3eE1qQTNmREI4TUh4d2FHOTBieTF3WVdkbGZIeDhmR1Z1ZkRCOGZIeDhmQT09Jml4bGliPXJiLTQuMS4wJnE9NjAmdz0zMDAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.unsplash.com/photo-1504639725590-34d0984388bd/query-Zm09anBnJml4aWQ9TTN3eE1qQTNmREI4TUh4d2FHOTBieTF3WVdkbGZIeDhmR1Z1ZkRCOGZIeDhmQT09Jml4bGliPXJiLTQuMS4wJnE9NjAmdz0zMDAw"/></p>
<p>照片由 Kevin Ku 提供于 Unsplash</p>
<p>投资者通常依赖医疗保健行业来保护他们的投资。这是因为医疗服务的需求在市场条件下变化不大，因此该行业为投资的资本提供了足够的保护。许多制药公司还提供定期分红。持续支付分红的公司在财务上是稳定的，并且无论市场条件如何，都能产生稳定的现金流。对于希望进入该行业的投资者来说，互惠基金是完美的选择，因为它们具有广泛的多样化和分析洞察的优势。</p>
<p>以下是我们为您分享的三只排名靠前的医疗保健互惠基金，分别是 <strong>Fidelity Select Health Care</strong>(FSPHX - 免费报告)、<strong>Fidelity Select Biotechnology Portfolio</strong>(FBIOX - 免费报告) 和 <strong>Fidelity Advisor Biotechnology Fund</strong> (FBTIX - 免费报告)。每只基金都获得了 Zacks 互惠基金排名 #1（强力买入），预计未来将优于同类基金。</p>
<p><strong>Fidelity Select Health Care</strong> 专注于全球医疗保健股票，投资于提供医疗产品或服务的公司。FSPHX 顾问使用基本面分析来评估财务实力、行业地位和市场条件，同时保持非多样化的投资组合。</p>
<p>Fidelity Select Health Care 的三年年化回报率为 7.9%。截至 2025 年 8 月，FSPHX 持有 117 只股票，其中 7.5% 的资产投资于波士顿科学公司。</p>
<p><strong>Fidelity Select Biotechnology Portfolio</strong> 以全球生物技术股票为目标，投资于推动科学和技术进步的公司，并应用基本面分析来评估财务健康、行业地位和更广泛的市场条件，同时保持非多样化的投资方式。</p>
<p>Fidelity Select Biotechnology Portfolio 的三年年化回报率为 16.9%。FBIOX 的费用比率为 0.63%。</p>
<p><strong>Fidelity Advisor Biotechnology Fund</strong> 专注于全球生物技术相关股票，目标是推动科学和技术进步的公司，使用基本面分析来评估财务实力、行业地位和更广泛的市场条件，同时保持非多样化的投资组合。</p>
<p>Fidelity Advisor Biotechnology Fund 的三年年化回报率为 19.7%。Eirene Kontopoulos 自 2018 年 7 月以来一直担任 FBTIX 的基金经理。</p>
<hr/>
<p><em>更多来自此作者的文章：</em></p>
<p>制药行业对美国的 3700 亿美元押注：2026 年的 ETF 投资机会</p>
<p>中国和新兴市场稳定？2026 年的三只全球奢侈品股票</p>
<p>银行 ETF 表现亮眼，因美国银行利润在第三季度创下十年新高</p>

<p>这篇文章强调了三只排名靠前的医疗保健共同基金：Fidelity Select Health Care (FSPHX)、Fidelity Select Biotechnology Portfolio (FBIOX) 和 Fidelity Advisor Biotechnology Fund (FBTIX)。这些基金获得了 Zacks 共同基金排名#1（强烈买入），预计将超过同行。FSPHX 专注于全球医疗保健股票，三年年化回报率为 7.9%。FBIOX 则瞄准生物技术股票，回报率为 16.9%，费用比率为 0.63%。FBTIX 同样专注于生物技术股票，自 2018 年以来由 Eirene Kontopoulos 管理，回报率为 19.7%</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.unsplash.com/photo-1504639725590-34d0984388bd/query-Zm09anBnJml4aWQ9TTN3eE1qQTNmREI4TUh4d2FHOTBieTF3WVdkbGZIeDhmR1Z1ZkRCOGZIeDhmQT09Jml4bGliPXJiLTQuMS4wJnE9NjAmdz0zMDAw" alt="" original-src="https://images.unsplash.com/photo-1504639725590-34d0984388bd?fm=jpg&amp;q=60&amp;w=3000&amp;ixlib=rb-4.1.0&amp;ixid=M3wxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8fA%3D%3D"/></p>
<p>Photo by Kevin Ku on Unsplash</p>
<div class="lb-trans"><p>照片由 Kevin Ku 提供于 Unsplash</p>
</div><p>Investors often rely on the healthcare sector to safeguard their investments. This is because the demand for healthcare services does not vary too much with respect to market conditions, and thus, the sector offers sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends. Companies that consistently pay out dividends are financially stable and generate steady cash flows, irrespective of market conditions. Mutual funds are the perfect choice for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.</p>
<div class="lb-trans"><p>投资者通常依赖医疗保健行业来保护他们的投资。这是因为医疗服务的需求在市场条件下变化不大，因此该行业为投资的资本提供了足够的保护。许多制药公司还提供定期分红。持续支付分红的公司在财务上是稳定的，并且无论市场条件如何，都能产生稳定的现金流。对于希望进入该行业的投资者来说，互惠基金是完美的选择，因为它们具有广泛的多样化和分析洞察的优势。</p>
</div><p>Below, we share with you three top-ranked Healthcare mutual funds, namely <strong>Fidelity Select Health Care</strong>(FSPHX - Free Report) , <strong>Fidelity Select Biotechnology Portfolio</strong>(FBIOX - Free Report) and <strong>Fidelity Advisor Biotechnology Fund</strong> (FBTIX - Free Report) . Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) and is expected to outperform its peers in the future.</p>
<div class="lb-trans"><p>以下是我们为您分享的三只排名靠前的医疗保健互惠基金，分别是 <strong>Fidelity Select Health Care</strong>(FSPHX - 免费报告)、<strong>Fidelity Select Biotechnology Portfolio</strong>(FBIOX - 免费报告) 和 <strong>Fidelity Advisor Biotechnology Fund</strong> (FBTIX - 免费报告)。每只基金都获得了 Zacks 互惠基金排名 #1（强力买入），预计未来将优于同类基金。</p>
</div><p><strong>Fidelity Select Health Care</strong> focuses on global healthcare stocks, investing in companies providing medical products or services. FSPHX advisors use fundamental analysis to evaluate financial strength, industry position and market conditions, while maintaining a non-diversified portfolio.</p>
<div class="lb-trans"><p><strong>Fidelity Select Health Care</strong> 专注于全球医疗保健股票，投资于提供医疗产品或服务的公司。FSPHX 顾问使用基本面分析来评估财务实力、行业地位和市场条件，同时保持非多样化的投资组合。</p>
</div><p>Fidelity Select Health Care has three-year annualized returns of 7.9%. As of August 2025, FSPHX held 117 issues, with 7.5% of its assets invested in Boston Scientific.</p>
<div class="lb-trans"><p>Fidelity Select Health Care 的三年年化回报率为 7.9%。截至 2025 年 8 月，FSPHX 持有 117 只股票，其中 7.5% 的资产投资于波士顿科学公司。</p>
</div><p><strong>Fidelity Select Biotechnology Portfolio</strong> targets global biotechnology stocks, investing in companies driving scientific and technological advances, and applies fundamental analysis to assess financial health, industry standing and broader market conditions, while maintaining a non-diversified investment approach.</p>
<div class="lb-trans"><p><strong>Fidelity Select Biotechnology Portfolio</strong> 以全球生物技术股票为目标，投资于推动科学和技术进步的公司，并应用基本面分析来评估财务健康、行业地位和更广泛的市场条件，同时保持非多样化的投资方式。</p>
</div><p>Fidelity Select Biotechnology Portfolio has three-year annualized returns of 16.9%. FBIOX has an expense ratio of 0.63%.</p>
<div class="lb-trans"><p>Fidelity Select Biotechnology Portfolio 的三年年化回报率为 16.9%。FBIOX 的费用比率为 0.63%。</p>
</div><p><strong>Fidelity Advisor Biotechnology Fund</strong> focuses on biotech-related stocks worldwide, targeting firms driving scientific and technological advances, using fundamental analysis to assess financial strength, industry position and broader market conditions, while maintaining a non-diversified portfolio.</p>
<div class="lb-trans"><p><strong>Fidelity Advisor Biotechnology Fund</strong> 专注于全球生物技术相关股票，目标是推动科学和技术进步的公司，使用基本面分析来评估财务实力、行业地位和更广泛的市场条件，同时保持非多样化的投资组合。</p>
</div><p>Fidelity Advisor Biotechnology Fund has three-year annualized returns of 19.7%. Eirene Kontopoulos has been the fund manager of FBTIX since July 2018.</p>
<div class="lb-trans"><p>Fidelity Advisor Biotechnology Fund 的三年年化回报率为 19.7%。Eirene Kontopoulos 自 2018 年 7 月以来一直担任 FBTIX 的基金经理。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p><em>More By This Author:</em></p>
<div class="lb-trans"><p><em>更多来自此作者的文章：</em></p>
</div><p>Pharma's $370 Billion Bet On America: The ETF Plays For 2026</p>
<div class="lb-trans"><p>制药行业对美国的 3700 亿美元押注：2026 年的 ETF 投资机会</p>
</div><p>China, Emerging Markets Stabilizing? 3 Global Luxury Stocks For 2026</p>
<div class="lb-trans"><p>中国和新兴市场稳定？2026 年的三只全球奢侈品股票</p>
</div><p>Bank ETFs Shine As US Banking Profit Hits Decade High In Q3</p>
<div class="lb-trans"><p>银行 ETF 表现亮眼，因美国银行利润在第三季度创下十年新高</p>
</div>

三只顶级排名的医疗保健共同基金有望实现强劲增长